שווי כולל של החברה: Synlogic (SYBX)

Synlogic, Inc. (SYBX) develops engineered bacteria to combat gastrointestinal toxins, with its market capitalization based on a synthetic biotic platform and licensing royalties. This chart illustrates the enterprise value at -9.04. However, management is currently conducting a rigorous restructuring following the suspension of key development programs, leading the market to value the company primarily on the basis of its liquidation assets.

For Synlogic, Inc. (SYBX), which is currently undergoing a strategic review, the change in enterprise value serves as an indicator of the actual acquisition price. This metric aggregates market capitalization and debt, minus available cash. Such a calculation reveals the actual cost of buying out all assets, accounting for the debt load. Amid restructuring, this indicator remains sensitive to credit risks. The trend of this indicator determines the financial stability of Synlogic, Inc. (SYBX) while seeking new alternatives.